UK markets open in 5 hours 30 minutes

Compass Therapeutics, Inc. (CMPX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.8000-0.0500 (-2.70%)
At close: 04:00PM EST
1.8000 0.00 (0.00%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.8500
Open1.8300
Bid1.7800 x 800
Ask1.9100 x 800
Day's range1.7110 - 1.8500
52-week range1.1500 - 4.0000
Volume142,324
Avg. volume538,400
Market cap229.475M
Beta (5Y monthly)0.38
PE ratio (TTM)N/A
EPS (TTM)-0.3300
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.17
  • GlobeNewswire

    Compass Therapeutics Provides Corporate Update

    We continue to open clinical sites and enroll patients in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). Consistent with prior guidance, top line data from this study continue to be expected in the second half of 2024.Enrollment of patients in COMPANION-003, the Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC), has been extended into the first quarter of 2024. We expect t

  • Simply Wall St.

    Compass Therapeutics Insider Ups Holding During Year

    Viewing insider transactions for Compass Therapeutics, Inc.'s ( NASDAQ:CMPX ) over the last year, we see that insiders...

  • GlobeNewswire

    Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

    Opened 29 clinical sites and continue to enroll patients in COMPANION-002, a U.S. Phase 2/3 study of CTX-009 in combination with Paclitaxel in patients with advanced biliary tract cancers (BTC); top line data from this study is expected in the second half of 2024Continue to enroll and follow patients in COMPANION-003, a U.S. Phase 2 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced colorectal cancer (CRC); initial data from this study is expected before the end of the